scispace - formally typeset
C

Christina Nowack

Researcher at Bayer

Publications -  27
Citations -  3064

Christina Nowack is an academic researcher from Bayer. The author has contributed to research in topics: Finerenone & Kidney disease. The author has an hindex of 16, co-authored 24 publications receiving 1751 citations. Previous affiliations of Christina Nowack include Bayer HealthCare Pharmaceuticals & Bayer Corporation.

Papers
More filters
Journal ArticleDOI

Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply.

TL;DR: Although Dr Feng and colleagues are correct that change in UACR at day 90 was the primary end point, it is understood this is not consistent with any valid renal outcome and is a marker of inflammation and cardiovascular risk rather than renal injury.
Journal ArticleDOI

Position Statement from ADA/AACE/EASD/TES in Response to a Recently Published Letter to the Editor in The Lancet and an Editorial Addressing the Israeli-Palestinian Fighting in Gaza

TL;DR: The aim of this work is to contribute towards the humanizing of endocrinology by promoting awareness of the importance ofocrinology in the care and treatment of patients withocrine-related illnesses.
Patent

Préparation combinée comprenant de la finérénone et du valsartan

TL;DR: La presente invention concerne l'utilisation de l'agoniste du recepteur mineralocorticoide finerenone en combinaison avec le Valsartan, un agoniste de l-angiotensine AII, pour traiter et/ou prevenir des troubles du systeme cardiovasculaire, des troubles renaux, des problems pulmonaires and pour traiting et/u prevenIR des troubles fibrotiques.
Journal ArticleDOI

Pos-350 finerenone in mild to severe chronic kidney disease and type 2 diabetes: the fidelity prespecified pooled analysis

TL;DR: In this article , the authors evaluated the effects of finerenone on composite kidney and cardiovascular endpoints in varying stages of CKD (defined by estimated glomerular filtration rate [eGFR] and urine albumin-to-creatinine ratio [UACR]).